Overview

Faslodex in McCune Albright Syndrome

Status:
Active, not recruiting

Trial end date:
2023-07-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called Faslodex (fulvestrant) in the treatment of progressive precocious puberty (early puberty) in girls with McCune-Albright syndrome (MAS).

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Fulvestrant